If a provider is vague about this, thats a warning sign
For instance, Zhang et al 28 indicated in their study that the microbiota-intestinal barrier-atrial NLRP3 inflammatory body axis may be a reasonable molecular target for the treatment of senile arrhythmia diseases
The liver and the gut are connected by the portal vein, creating a continuous feedback loop known as the gut-liver axis
The main difference is that Mounjaro, which works on both GLP-1 and GIP receptors, may offer enhanced results compared to Ozempic, which only targets the GLP-1 receptor
They warn that the lack of rigorous clinical trials and standardized protocols raise serious safety concerns, including the risk of hepatotoxicity (liver damage caused by chemicals) and allergic reactions like anaphylaxis
The India advantage India is emerging as a preferred hub for both pharma and medical devices, offering a strategic advantage in the GLP-1 race